Day One Biopharmaceuticals, Inc. received FDA approval for OJEMDA, driving strong revenue growth and expansion opportunities in pediatric low-grade glioma. DAWN announces acquisition of Mersana ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback